Suicide gene therapy combining herpes simplex virus thymidine kinase gene transfer and ganciclovir administration can be envisioned as a powerful therapeutical approach in the treatment of hepatocellular carcinoma; however, safety issues regarding transgene expression in parenchyma cells have to be addressed. In this study, we constructed LATKW, a lentiviral vector expressing the HSV-TkEGFP gene placed under the control of the promoter elements that control the expression of the rat alpha-fetoprotein, and assayed its specific expression in vitro in hepatocarcinoma and nonhepatocarcinoma human cell lines, and in epidermal growth factor stimulated human primary hepatocytes. Using LATKW, a strong expression of the transgene was found in transduced hepatocarcinoma cells compared to a very low expression in nonhepatocarcinoma human cell lines, as assessed by Northern blot, RT-PCR, FACS analysis and ganciclovir-mediated toxicity assay, and no expression was found in lentivirally transduced normal human hepatocytes. Altogether, these results demonstrate the possibility to use a lentivirally transduced expression unit containing the rat alpha-fetoprotein promoter to restrict the HSV-TK-mediated induced GCV sensitivity to human hepatocarcinoma cells.
H epatocellular carcinoma (HCC) is a common tumor, usually associated with liver cirrhosis or chronic infection with hepatitis B or C viruses. [1] [2] [3] Its incidence has increased in Europe, Japan and North America. 4, 5 The chemotherapeutical treatment of HCC remains difficult and most of the patients cannot benefit from tumor resection or liver transplantation due to the underlying liver disease or the extension of the tumor at the time of diagnosis. [6] [7] [8] [9] Suicide gene therapy combining herpes simplex virus thymidine kinase (HSV-Tk) gene transfer and ganciclovir (GCV) administration can be envisioned as a potential therapeutical approach as it has been proven in the treatment of hepatocellular carcinoma in different animal models. 10, 11 However, transduction of normal hepatocytes and subsequent phosphorylation of GCV within the normal liver may induce a severe hepatitis. [11] [12] [13] Considering that HCC usually occurs in a background of chronic liver disease or cirrhosis, acute hepatitis may be particularly deleterious in such patients. To avoid this side effect, gene therapy vectors have to be designed to target the transfer and/or to restrict the expression of the transgene to HCC cells. 11, 14 Human immunodeficiency virus type 1 (HIV)-derived lentiviral vectors have been shown to be very efficient in transducing dividing and nondividing HCC cells in vitro and in vivo and can be considered as attractive tools to develop new gene therapy strategies for hepatocellular carcinoma. 15, 16 Although the possibility to transduce HCC cells more efficiently than quiescent normal hepatocytes under certain conditions has been suggested, it should be considered that in the context of HCC, which is characterized by the development of regeneration nodules and an increased proliferation index of parenchyma cells, normal hepatocytes may exhibit an increased sensitivity to lentiviral transduction. In this respect, safety strategies including the targeting of the expression of the therapeutic transgene in HCC have to be developed. In this work, we took advantage of the possibility to efficiently transduce in vitro HCC cell lines and epidermal growth factor (EGF) stimulated primary hepatocytes with lentiviral vector to demonstrate the possibility to restrict the expression of a transgene of interest to human tumor cells. For this purpose, HSV-TkEGFP, a gene encoding a fusion protein exhibiting the marking activity of the enhanced version of the green fluorescent protein (EGFP) and the potential therapeutic activity of the thymidine kinase encoded by the HSV-TK gene, was placed in a lentiviral vector under the control of the rat promoter elements driving the expression of the alpha-fetoprotein (AFP) and used to transduce normal human hepatocytes and cancer cells. 17 Both fluorescence activity and GCVmediated cytotoxicity were used to assay the activity of the transgene in transduced cells.
Methods

Production and characterization of vectors
To generate pLCTK, the 1. 8-kb SalI-BamHI fragment of pCALNL containing the CAG promoter 18 was inserted between XhoI and BamHI in the pRRL 0 PGK-GFP.SIN18 plasmid (kindly provided by D Trono, University of Geneva, Switzerland) in place of the phosphoglycerate kinase promoter. Then, the 1.9-kb SalI-BsrGI fragment from the pTKGFP plasmid (kindly provided by Dr M Slack, MPI, Ko¨ln, Germany) containing the HSVTkEGFP coding sequence was inserted between SalI and BsrGI in place of the EGFP gene. To generate pLATK, the BstXI-XhoI 3.2-kb fragment with the rat AFP transcriptional regulatory sequence was released from pBS-AFP (kindly provided by JL Danan, CNRS, Meudon, France) and inserted between the SpeI and the XhoI site in place of the CAG promoter. The 600-bp EcoRI-EcoRI fragment of the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was inserted in sense orientation into EcoRI in pLCTK and pLATK. 19 Lentiviral vector particles were produced in 293 T cells using a polyethylenimine (Aldrich, Milwaukee, WI) mediated transfection procedure. 293 T cells were transfected with (i) the packaging plasmid pCMVDR8.91 which expresses HIV-1 gag, pol, tat and rev proteins, (ii) the envelope plasmid pMD-G which expresses the vesicular stomatitis virus envelope G glycoprotein (VSV-G) and (iii) pLCTKW or pLATKW. 20 Conditioned medium was harvested 48 and 72 hours after transfection, cleared of debris by low-speed centrifugation, filtered through 0.22 mm membrane and concentrated using Vivaspin 20 100,0000 MWCO PES membrane (Vivascience, Binbrook, UK) by centrifugation at 4000 r.p.m. for 1 hour at 151C in a Beckman G6SK-R centrifuge (Beckman Instruments, Palo Alto, CA). Determination of the p24 capsid protein content in concentrated viral vector stocks was performed by enzyme link immunosorbent assay (NEN Life Science Products, Paris, France).
Cell lines culture and transduction
The hepatoma (HuH7 and HepG2) and nonhepatoma (TE671, 293 T and HelaP4) human cell lines were cultured in Dulbecco's modified eagle medium supplemented with 10% fetal bovine serum. Quantitative analysis of AFP secretion was performed with the AFP Amerlex-M RIA detection kit (Ortho Clinical Diagnostics, Issy les Moulineaux, France). For transduction experiments, 1 Â 10 5 cells per well were seeded into 12-well multiplates and were incubated for 16 hours in 0.5 ml of fresh medium supplemented with the viral vector containing supernatant (250 ng of p24 per well) in the presence of 4 mg/ml of polybrene (Sigma, St Louis, MO). The cells were then cultured in complete medium for 6 days prior to analysis.
GCV-mediated cytotoxicity assay
In total, 1 Â 10 4 cells per well were seeded into a 96-well multiplate. After 24 hours and up to day 4, the culture medium was replaced with 100 ml of a fresh culture medium supplemented with different concentrations of GCV (Roche, Neuilly-Sur-Seine, France). To quantify the cell viability, 10 ml of Cell Proliferation Reagent WST-1 (Boehringer Mannheim, Mannheim, Germany) were added in each well on day 4 for 4 h at 371C. The color reaction was quantified using an automatic plate reader (Dynatech, MR5000, Chantilly, VA) at 450 nm with a reference filter of 630 nm. The percentage of viable cells was calculated as follows: % viable cells ¼ A/B Â 100, where A is the absorbance from the cells incubated with GCV and B is the absorbance from the cells incubated with the culture medium alone.
Isolation and transduction of primary human hepatocytes
Human primary adult hepatocytes (HPAH) were derived from liver pieces obtained after partial hepatectomy from liver metastasis and isolated using a two-step collagenase perfusion technique. Briefly, the liver piece was extensively washed in situ with PBS prior to be moved to the laboratory in a 41C container. The liver piece was placed in a perfusion apparatus and perfused with a calcium-free buffer (142 mM NaCl, 3 mM KCl, 0.2 mM Na 2 HPO 4 , 10 mM Hepes, pH 7.65, 371C) followed by a perfusion with the same solution supplemented with 10 mM CaCl 2 and 0.04% collagenase (Invitrogen, Cergy Pontoise, France). The liver was dissociated, filtered through gauze, washed three times with Ham F12 media and resuspended in hepatocytes basal medium (HBM) supplemented with HCM singlequots containing ascorbic acid, fatty acid free bovine serum albumin, hydrocortisone, transferrin, insulin and human epidermal growth factor (EGF; BioWhittaker, Emerainville, France). Freshly isolated hepatocytes were seeded into a 24-well plate coated with collagen I (2.5 Â 10 5 cells/well). At 1 day after isolation, HPAH were incubated for 16 h with the same amount of LATKW and LCTKW particles as assessed by the p24 content (250 ng p24 per well). 6 days after transduction, the percentage of EGFP-expressing cells and the mean fluorescence index (MFI) were determined by FACS analysis. Pseudotransduction was assayed by transduction of the HPAH with LCTKW in the presence of 37 mM reverse-transcriptase-inhibitor zidovudine (Glaxo Well-come, Paris, France). Cells were cultured for about 1 week, and according to iodure propidium staining and cell phenotype under visual microscopy no artefactual mortality was detected for the 5-6 first days of the culture.
Northern blot analysis
Total RNA was extracted from parental and lentivirally transduced cells by TRIZOL Reagent (Invitrogen, Cergy Pontoise, France) according to the protocol provided by the manufacturer. In all, 20 mg of the RNA suspended in 10 mM phosphate buffer (pH 7.0), glyoxal (18%) and dimethyl sulfoxide (50%) was subjected to electrophoresis on 1% agarose gel and transferred to nylon membranes (Biodine A Pall-Bio-support, Portsmouth, UK). P 32 -radiolabelled HSV-TkEGFP and actin cDNA probes were used to evaluate the expression of the HSV-TkEGFP gene and to monitor the loading of the RNA samples, respectively.
PCR and RT-PCR analysis
For the detection of HSV-TkEGFP-containing sequences in the cellular genome, PCR was performed using 1 mg of genomic DNA extracted from parental and lentivirally transduced cells with the NucleoSpin Tissue kit (Macherey-Nagel, Du¨ren, Germany). Amplification of genomic DNA was performed on whole-cell extracts with HSVTkEGFP-specific primers (sense primer 5 0 -CAA-TACGGTGCGGTATCTGC-3 0 and antisense primer 5 0 -GCTTCTCGTTGGGGTCTTTG-3 0 ). PCR conditions were 1 minute denaturation at 951C, 1 minute annealing at 571C, and 1 minute extension at 721C for 35 cycles and a final extension for 10 minutes at 721C, yielding a 1046-bp product. For RT-PCR, RNA samples were obtained as described above, and complementary DNA was generated using the Thermoscript RT-PCR system following the manufacturer's instructions (Invitrogen, Cergy Pontoise, France). A volume of 2 ml of the RT reaction product was subjected to PCR as described above with the HSVTkEGFP-specific primers to generate a 1046-bp specific product corresponding to the HSV-TkEGFP cDNA sequence. PCR and RT-PCR with b-actin-specific primers were performed under the same conditions.
Statistical analysis
The statistical analyses were performed using the Student's t-test. A P-valueo.05 was considered statistically significant.
Results
Construction of a lentiviral vector designed to express the HSV-TkEGFP gene in AFP-producing cells
Considering that some hepatocarcinoma specifically express the AFP, LATKW, a monocistronic lentiviral vector, was constructed to express the HSV-TkEGFP gene under the control of the biological pathways leading to the transcription of the AFP gene (Fig 1a) . For this purpose, the HSV-TkEGFP cDNA was placed under the control of the transcriptional regulatory sequences located -3127 to +102 with respect to the transcription start site of the rat AFP gene in a lentiviral vector backbone, thus allowing the generation of a 2.5 kb long transcript (Fig 2) . This region contains the most proximal three enhancers, the region homologous to the putative murine AFP silencer and the promoter region. This expression unit was inserted in a self-inactivating HIV-1-derived vector backbone to enable the elimination of the promoter elements located in the U3 sequence of the long terminal repeat (LTR) in transduced cells, thus preventing from interferences between the endogenous AFP promo- Gene therapy of hepatocarcinoma using lentiviral vector R Uch et al ter and the viral flanking promoter elements. LCTKW, a similar vector with the HSV-TkEGFP cDNA placed under the control the CAG ubiquitous promoter, was used as control (Fig 1b) . In order to increase the expression, the WPRE was inserted in the two vectors in sense orientation downstream the transgene of interest.
LATKW is able to promote the expression of the HSV-TkEGFP gene in tumorous cells and not in normal hepatocytes
Considering that a lentiviral vector designed to treat HCC should not drive the expression of the therapeutic transgene in parenchyma cells, we evaluated the ability of LATKW to transduce normal hepatocytes in vitro without expressing the transgene. Production of AFP was assayed in both hepatoma and nonhepatoma cells (Table 1) . No expression of AFP was detected in normal human hepatocytes. HuH7 and HepG2 were selected as model target cell lines for AFP-expressing hepatoma cells of human origin, and Hela, 293 T and Te671 were selected as control for human cells not expressing the AFP. HepG2, HuH7, TE671, 293 T cells and prestimulated fresh human primary hepatocytes were transduced with LATKW and LCTKW using viral vector samples containing 250 ng of p24. Efficient transduction of primary hepatocytes with lentiviral vectors has been shown to be difficult to achieve without the addition of growth factors (data not shown), and normal hepatocytes as targets were prestimulated with human epidermal growth factor prior to transduction. 6 days after transduction, cell population was assayed for GFP expression by FACS analysis. Photomicrographs of fluorescent HepG2 and HuH7 transduced with LATKW are shown in Fig. 3 . As shown in Table 2 , AFP-producing HuH7 and HepG2 cells were efficiently transduced with LATKW vector. The value of the relative MFI, defined as the ratio of the MFI obtained with transduced and mock transduced cells, ranged from 14 to 19, thus approximately 7-to 10-fold lower than transduced cells expressing HSV-TkEGFP placed under the control of the CAG promoter. RT-PCR analyses performed with HSVTkEGFP gene specific primers showed the presence of HSV-TkEGFP transcripts in LATKW-transduced TE671 cells (Fig 4) . In the total RNA content of transduced HuH7, a unique band of 2.5 kb that corresponds to the expected size of the HSV-TkEGFP mRNA driven by the AFP regulatory elements was found hybridizing with the P 32 -radiolabelled HSV-TkEGFP probe (Fig 2) . Interestingly, the FACS analysis of TE671 and 293 T nonhepatoma cells transduced with LATKW vector showed a lower percentage of GFP-positive cells and a very low MFI. Conversely, human primary hepatocytes transduced with LATKW did not exhibit a significant EGFP expression as determined by FACS analysis nor showed transcripts containing the HSV-TkEGFP sequences as assayed by RT-PCR analysis. Presence of the viral vector genome as a DNA molecule in the transduced cells was confirmed by PCR analysis (Fig 4) . Hepatocytes transduced with LCTKW showed strong expression of the HSV-TkEGFP as assessed by FACS analysis in accordance with the detection of HSV-TkEGFP sequences amplified by RT-PCR (Table 2, Fig 4) . Less than 2% of EGFP-expressing cells were obtained when HPAH were transduced with LCTKW in the presence of 37 mM reverse-transcriptase-inhibitor zidovudine (Glaxo Wellcome, Paris, France) that confirms the very low level of pseudo-transduction in these experiments.
LATKW induces sensitivity to GCV-mediated toxicity only in AFP-expressing cells
In order to investigate the ability of the LATKW vector to mediate significant sensitivity toward the prodrug GCV only in AFP-expressing cells, genetically manipulated HepG2, HuH7 and TE671 cells were treated with 0-50 mM of GCV for 5 days. Surviving cells as assessed by WST-1 cell proliferation assay were determined as the percentage of non-GCV-treated controls. As shown in Gene therapy of hepatocarcinoma using lentiviral vector R Uch et al
Discussion
Gene therapy is an attractive strategy for the treatment of hepatocarcinoma, but this approach remains to be firmly secured to avoid side effects due to unexpected expression of the transgene in nontumorous hepatocytes and subsequent elimination of normal cells. 11, 12 In this work, we analyzed the expression of a lentivirally transduced HSV-TkEGFP gene placed under the control of the rat AFP promoter in normal human hepatocytes and in human hepatocarcinoma cell lines. Previous works clearly showed that the use of rat or human AFP promoter can prevent transgene expression in vitro in non-HCC cell lines and in vivo in the rat normal liver. The efficiency of the rat AFP promoter in human normal primary hepatocytes has not been evaluated so far. [21] [22] [23] 24 This study demonstrated that the lentiviral transduction of the HSV-TkEGFP fusion gene placed under the control of the rat AFP regulatory elements prevents HSVTkEGFP expression in normal human hepatocytes, even as assayed at the transcription level by RT-PCR, while strong expression was found in AFP-producing HCC cells. It should be noted that compared to the CAG ubiquitous promoter, which drives the expression of HSV-TkEGFP in LCTKW, transgene expression was found significantly lower when placed under the control of the AFP promoter. The absence of LATKW expression in primary hepatocytes suggests that the use of AFP regulatory elements of murine origin not fully adapted to the human context may both induce a low expression in permissive human cells and favor a strong silencing of the promoter in human hepatocytes that do not express the AFP. The use of a self-inactivating backbone to construct LATKW has also to be considered as a key feature of this Figure 4 PCR and RT-PCR analysis of lentivirally transduced cells. Genomic DNA and total RNA were isolated from HuH7, TE671 and primary human stimulated hepatocytes transduced or not with LCTKW or LATKW, and submitted to PCR-(a) or RT-PCR-based (b) analysis, respectively, using primers specific to the HSV-TkEGFP-coding sequence or primers specific to the actin-coding sequence. Lanes 1, 4 and 7 are respectively mock transduced HuH7, TE671 and hepatocytes; lanes 2, 5 and 8 are respectively LCTKW-transduced HuH7, TE671 and hepatocytes; lanes 3, 6 and 9 are respectively LATKW-transduced HuH7, TE671 and hepatocytes. Gene therapy of hepatocarcinoma using lentiviral vector R Uch et al absence of expression since this backbone configuration avoids an unexpected expression of the transgene resulting from interferences between the endogenous promoter and the viral regulatory elements located in the LTR. Nevertheless, when using LATKW, HSV-TkEGFP expression was found sufficient to induce 80% cell death at low GCV concentrations. Interestingly, when using TE671 or 293 T, two malignant nonhepatic human tumor cells, as target cells, LATKW allows 30% of the cell population to express the HSV-TkEGFP gene as assessed by FACS analysis. This result was not artefactual since HSV-TkEGFP mRNA was detected by RT-PCR analysis in these cells. However, HSV-TkEGFP expression in these non-HCC cells was found weak. EGFP fluorescence could be detected only by FACS and not by microscopical examination. Such a nonspecific expression of the transgene in AFP nonproducing cell lines has not been previously reported when using the AFP promoter. This may be related to the use of very sensitive methods to detect the transgene expression in this study, while in previous works less sensitive assays, such as X-Gal staining or GCV sensitivity, were used. [21] [22] [23] 25 Indeed, in accordance with the previously reported results, LATKW-induced HSV-TkEGFP expression was not strong enough to induce GCV-mediated toxicity in AFP nonproducing cell lines. This observation suggests that the overexpression of AFP in HCC cells could result from the conjunction of activation pathways, some of them being shared by tumor cells regardless of the cell type. In addition, it highlights that a vector able to transfer a therapeutic gene has to be studied not only considering both its expression at the molecular level and its efficiency to promote the biological effect of the transgene selected but also its ability to drive the expression of a marker gene. It has to be noted that the GCV-mediated toxicity requires several days to kill the cells and relies on the proliferative ability of the target cells expressing HSV-TK. Normal hepatocytes naturally exhibit a poor proliferative ability in vitro and, in addition, we evaluated the expression of LATKW and LCTKW in stringent experimental conditions allowing normal human hepatocytes not to proliferate as expected in the normal liver. Altogether, this context makes the evaluation of the GCV killing/resistance of normal hepatocytes transduced by LCTKW or LATKW difficult.
It has to be emphasized that the development of a relevant animal model to assess such a strategy in vivo remains a very difficult issue to address, since there is no animal model supporting the coordinated growth of normal human hepatocytes and human HCC cells. Animal models close to the human pathology, such as chemically induced HCC in rats or woodchuck hepatitis virus-induced HCC in the woodchuck model, 11, 26 could not be envisaged because the behavior of the rat regulatory elements in the murine context would not be relevant for the expression in vivo of the murine AFP promoter in a human HCC context. In addition, although the normal parenchyma shows some important proliferative ability under stress conditions, a relevant animal model mimicking the true mechanisms underlying the potential cell-to-cell contacts between HCC and normal hepatocytes should be very useful to study the bystander effect mediated killing of normal hepatocytes by GCV treated HCC cells. 27 Altogether, our results suggest that LATKW can be envisioned as a very efficient and secure vector for suicide gene therapy of AFP-expressing human HCC. LATKW combines a tumor cell specific transcriptional targeting and the absence of elements of human origin sequence that reduces the possibility to recombine with genome elements. Although a relevant animal model remains to be developed to firmly evaluate this strategy in vivo, this vector and this strategy are likely to avoid severe side effects related to uncontrolled expression of the transgene in normal cells if lentiviral-mediated HSV-TkEGFP suicide gene therapy is employed in humans. Hepatoma (HuH7 and HepG2), nonhepatoma (TE671 and 293T) cell lines and human primary stimulated hepatocytes were transduced with LATKW or LCTKW lentiviral vectors with a viral vector sample containing 250 ng of p24. The percentage of TkEGFPexpressing cells and the relative MFI were determined on day 6 posttransduction and expressed as the mean7S.D of three separate experiments.
